York life sciences business launches capsules in Germany Magazine
York life sciences business OptiBiotix Health has launched its LPLDL capsules in Germany.
HLH BioPharma Vertriebs GmbH has commenced commercial sales to German pharmacies.
This follows on from the three year supply agreement with HLH BioPharma Vertriebs GmbH announced on 15 June 2017.
HLH will market capsules containing LPLDL under the brand name Lactobact LDL-Control and promote them directly to the pharmacy market in Germany, as well as to consumers on their online platform.
Sales revenues are likely to be in the low to mid six figure in the near term growing as HLH builds market presence.
OptiBiotix CEO Stephen O’Hara said: “We hope this will be the first of many product launches of multiple formulations and presentations of LPLDL®as the active component in a wide range of pharmaceutical and consumer products around the world.
He added: “Establishing early sales of LPLDL to pharmacies with HLH helps substantiate the credibility in the science behind LPLDL to build the brand and acceptance in the larger consumer healthcare markets.”